rs11568372
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_003742.4(ABCB11):āc.890A>Gā(p.Glu297Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000265 in 1,613,006 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ).
Frequency
Genomes: š 0.00011 ( 0 hom., cov: 32)
Exomes š: 0.00028 ( 0 hom. )
Consequence
ABCB11
NM_003742.4 missense
NM_003742.4 missense
Scores
12
6
1
Clinical Significance
Conservation
PhyloP100: 7.99
Genes affected
ABCB11 (HGNC:42): (ATP binding cassette subfamily B member 11) The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance. The protein encoded by this gene is the major canalicular bile salt export pump in man. Mutations in this gene cause a form of progressive familial intrahepatic cholestases which are a group of inherited disorders with severe cholestatic liver disease from early infancy. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP3
MetaRNN computational evidence supports a deleterious effect, 0.955
PP5
Variant 2-168990819-T-C is Pathogenic according to our data. Variant chr2-168990819-T-C is described in ClinVar as [Pathogenic]. Clinvar id is 6590.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr2-168990819-T-C is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ABCB11 | NM_003742.4 | c.890A>G | p.Glu297Gly | missense_variant | 9/28 | ENST00000650372.1 | NP_003733.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ABCB11 | ENST00000650372.1 | c.890A>G | p.Glu297Gly | missense_variant | 9/28 | NM_003742.4 | ENSP00000497931 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000112 AC: 17AN: 152126Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
17
AN:
152126
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.000249 AC: 62AN: 248872Hom.: 0 AF XY: 0.000237 AC XY: 32AN XY: 134992
GnomAD3 exomes
AF:
AC:
62
AN:
248872
Hom.:
AF XY:
AC XY:
32
AN XY:
134992
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000281 AC: 411AN: 1460880Hom.: 0 Cov.: 31 AF XY: 0.000274 AC XY: 199AN XY: 726722
GnomAD4 exome
AF:
AC:
411
AN:
1460880
Hom.:
Cov.:
31
AF XY:
AC XY:
199
AN XY:
726722
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000112 AC: 17AN: 152126Hom.: 0 Cov.: 32 AF XY: 0.000108 AC XY: 8AN XY: 74314
GnomAD4 genome
AF:
AC:
17
AN:
152126
Hom.:
Cov.:
32
AF XY:
AC XY:
8
AN XY:
74314
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ExAC
AF:
AC:
37
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:17
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:9
Pathogenic, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | May 10, 2018 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, University Medical Center Utrecht | - | - - |
Pathogenic, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 19, 2022 | Published functional studies demonstrate a damaging effect (severe protein dysfunction) (Wang et al., 2002; Byrne et al., 2009); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 18987030, 17855769, 24991443, 19101985, 18395098, 15791618, 20683202, 28776642, 29761168, 28733223, 32581362, 31589614, 34016879, 31319225, 9806540, 12370274) - |
Pathogenic, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Mar 01, 2023 | PP3, PM2, PS3, PS4 - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jan 01, 2023 | ABCB11: PM2, PM3, PP1:Moderate, PP4:Moderate, PS3:Supporting, PS4:Supporting - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 24, 2024 | This sequence change replaces glutamic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 297 of the ABCB11 protein (p.Glu297Gly). This variant is present in population databases (rs11568372, gnomAD 0.04%). This missense change has been observed in individuals with progressive familial intrahepatic cholestasis (PMID: 9806540, 19101985). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 6590). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on ABCB11 protein function. Experimental studies have shown that this missense change affects ABCB11 function (PMID: 12370274, 17855769, 19101985). For these reasons, this variant has been classified as Pathogenic. - |
Progressive familial intrahepatic cholestasis type 2 Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | Oct 12, 2021 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 01, 2005 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Nov 03, 2017 | - - |
Benign recurrent intrahepatic cholestasis type 2 Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 27, 2024 | - - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 01, 2005 | - - |
ABCB11-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 28, 2024 | The ABCB11 c.890A>G variant is predicted to result in the amino acid substitution p.Glu297Gly. This variant has been reported to be pathogenic for intrahepatic cholestasis due to protein misfolding (Strautnieks et al. 1998. PubMed ID: 9806540; Strautnieks et al. 2008. PubMed ID: 18395098; Arnell et al. 2010. PubMed ID: 20683202; Wang et al. 2002. PubMed ID: 12370274). This variant is reported in 0.044% of alleles in individuals of European (Non-Finnish) descent in gnomAD. This variant is interpreted as pathogenic. - |
Cholestasis, intrahepatic, of pregnancy, 3 Pathogenic:1
Pathogenic, no assertion criteria provided | research | NIHR Bioresource Rare Diseases, University of Cambridge | - | - - |
Progressive familial intrahepatic cholestasis Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Jun 14, 2016 | Across a selection of available literature, the c.890A>G (p.Glu297Gly) variant has been identified in a homozygous state in at least 16 familial intrahepatic cholestasis patients, in a compound heterozygous state in 27 patients, and in a heterozygous state in four patients in whom a second variant was not identified (Strautnieks et al. 1998; Strautnieks et al. 2008; Arnell et al. 2008). The p.Glu297Gly variant was found in a heterozygous state in one of 250 controls and is reported at a frequency of 0.00049 in the European (Non-Finnish) population of the Exome Aggregation Consortium. In vitro functional studies demonstrated that the variant destroys a cryptic splice site, leading to approximately 50% of wild type splicing, and disrupts the processing and trafficking of the ABCB11 protein (Hayashi et al. 2005; Byrne et al. 2009). Based on the collective evidence, the p.Glu297Gly variant is classified as pathogenic for familial intrahepatic cholestasis. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Pathogenic
DEOGEN2
Pathogenic
D;D
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
.;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D
MetaSVM
Pathogenic
D
MutationAssessor
Pathogenic
H;H
MutationTaster
Benign
A
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;.
REVEL
Pathogenic
Sift
Uncertain
D;.
Sift4G
Uncertain
D;.
Polyphen
D;D
Vest4
MVP
MPC
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at